A calcifying fibrous tumor (CFT) is a benign tumor of unknown etiology. A calcifying fibrous tumor is rare in the intestinal tract. A calcifying fibrous tumor is characterized by hyalinized collagenous fibrous tissue, psammomatous or dystrophic calcification, and focal lymphoplasmacytic infiltrates on histology. Magnetic resonance imaging is the standard method for evaluating the lesions of the rectum, and CFTs should be considered in differentiating the rectal wall tumors. Herein, we report a case of a 68-year-old man with a rectal wall CFT.
{"title":"Calcifying fibrous tumor of the rectum - a case report","authors":"Tomislav Pavlović, Rosana Troskot-Perić, Sanja Trtica","doi":"10.20471/LO.2020.48.02-03.20","DOIUrl":"https://doi.org/10.20471/LO.2020.48.02-03.20","url":null,"abstract":"A calcifying fibrous tumor (CFT) is a benign tumor of unknown etiology. A calcifying fibrous tumor is rare in the intestinal tract. A calcifying fibrous tumor is characterized by hyalinized collagenous fibrous tissue, psammomatous or dystrophic calcification, and focal lymphoplasmacytic infiltrates on histology. Magnetic resonance imaging is the standard method for evaluating the lesions of the rectum, and CFTs should be considered in differentiating the rectal wall tumors. Herein, we report a case of a 68-year-old man with a rectal wall CFT.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47662502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-21DOI: 10.20471/LO.2020.48.02-03.14
B. Petrić-Miše
Ovarian cancer is the fifth most common cause of death among malignant diseases in women in Europe. The standard treatment is cytoreductive surgery, followed by platinum-taxane based chemotherapy. In patients with advanced disease, a valid option is a neoadjuvant chemotherapy followed by interval debulking surgery. Despite the progress in primary treatment, almost 70% of the patients relapse. There is a significant need for better first-line treatment to avoid or delay relapse and improve ovarian cancer outcomes. The most significant change involves the changes in the treatment schedule and new drugs in first-line chemotherapy. Bevacizumab is approved in first-line treatment combined with carboplatin and paclitaxel as it improves progression-free survival (PFS) in patients with a higher risk of recurrence. After achieving the response to first-line chemotherapy, maintenance therapy with poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors prolongs PFS in patients with homologous recombination deficiency (HRD). Patients with BRCA mutations obtain the most significant benefit.
{"title":"First-line treatment of advanced ovarian cancer: an expert update","authors":"B. Petrić-Miše","doi":"10.20471/LO.2020.48.02-03.14","DOIUrl":"https://doi.org/10.20471/LO.2020.48.02-03.14","url":null,"abstract":"Ovarian cancer is the fifth most common cause of death among malignant diseases in women in Europe. The standard treatment is cytoreductive surgery, followed by platinum-taxane based chemotherapy. In patients with advanced disease, a valid option is a neoadjuvant chemotherapy followed by interval debulking surgery. Despite the progress in primary treatment, almost 70% of the patients relapse. There is a significant need for better first-line treatment to avoid or delay relapse and improve ovarian cancer outcomes. The most significant change involves the changes in the treatment schedule and new drugs in first-line chemotherapy. Bevacizumab is approved in first-line treatment combined with carboplatin and paclitaxel as it improves progression-free survival (PFS) in patients with a higher risk of recurrence. After achieving the response to first-line chemotherapy, maintenance therapy with poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors prolongs PFS in patients with homologous recombination deficiency (HRD). Patients with BRCA mutations obtain the most significant benefit.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49639494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-21DOI: 10.20471/LO.2020.48.02-03.17
N. Antoljak
Colorectal cancer is the second most common malignant neoplasm and the second cause of death from malignancies in both sexes. In 2017, 3689 people were diagnosed in the Republic of Croatia. Two thousand ninety-five people died of colorectal cancer in 2019. Colorectal cancer is preventable, and it appears that smoking and obesity are factors that affect its onset. Physical inactivity is closely related to obesity, and the question is whether it can be an independent predictor of colon cancer. We searched the literature on Pubmed for the past five years, including systematic reviews and meta-analyses on the association between physical activity and colon cancer incidence. Studies are methodologically diverse and involve different approaches. In most observational studies, greater physical activity is associated with a lower incidence of colon cancer, while in the interventional studies, results were more diverse. In general, smoking tobacco products has a much greater effect on colon cancer development, but physical activity is linked to the onset of the disease and should be one of the prevention measures.
{"title":"The importance of physical activity in colorectal cancer prevention","authors":"N. Antoljak","doi":"10.20471/LO.2020.48.02-03.17","DOIUrl":"https://doi.org/10.20471/LO.2020.48.02-03.17","url":null,"abstract":"Colorectal cancer is the second most common malignant neoplasm and the second cause of death from malignancies in both sexes. In 2017, 3689 people were diagnosed in the Republic of Croatia. Two thousand ninety-five people died of colorectal cancer in 2019. Colorectal cancer is preventable, and it appears that smoking and obesity are factors that affect its onset. Physical inactivity is closely related to obesity, and the question is whether it can be an independent predictor of colon cancer. We searched the literature on Pubmed for the past five years, including systematic reviews and meta-analyses on the association between physical activity and colon cancer incidence. Studies are methodologically diverse and involve different approaches. In most observational studies, greater physical activity is associated with a lower incidence of colon cancer, while in the interventional studies, results were more diverse. In general, smoking tobacco products has a much greater effect on colon cancer development, but physical activity is linked to the onset of the disease and should be one of the prevention measures.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45184186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-21DOI: 10.20471/LO.2020.48.02-03.08
I. Kirac, Z. Misir, Vesna Vorih, Loris Ćurt, M. Šekerija, N. Antoljak
Background: In the past six months, Croatia faced a short lockdown and a slow return to most hospitals’ everyday activities. During the lockdown, our center, as a part of the University Hospital Centre specialized for solid cancer, was enabled to maintain most of the routine practices with the one-month colonoscopy exception. Aim: To determine the oscillation in the number of endoscopies and colorectal surgery for 13 months (six months pre and post COVID-19 lockdown). Materials and methods: From August 1st, 2019, until August 31st 2020, the hospital analytics determine the number of colonoscopies, screening colonoscopies, and surgeries. Results: During the given period number of detected and operated colorectal cancers was stable, except for April, when we mostly did not perform colonoscopies. Conclusion: We maintained a pre-COVID-19 pace in colorectal cancer treatment, colonoscopies, and colorectal surgery after epidemiological guidelines for colonoscopies and colorectal surgery were applied, owing to the relatively stable overall epidemiological situation.
{"title":"The impact of COVID-19 epidemiological restriction guidelines measures in a Croatian tertiary colorectal cancer center","authors":"I. Kirac, Z. Misir, Vesna Vorih, Loris Ćurt, M. Šekerija, N. Antoljak","doi":"10.20471/LO.2020.48.02-03.08","DOIUrl":"https://doi.org/10.20471/LO.2020.48.02-03.08","url":null,"abstract":"Background: In the past six months, Croatia faced a short lockdown and a slow return to most hospitals’ everyday activities. During the lockdown, our center, as a part of the University Hospital Centre specialized for solid cancer, was enabled to maintain most of the routine practices with the one-month colonoscopy exception. Aim: To determine the oscillation in the number of endoscopies and colorectal surgery for 13 months (six months pre and post COVID-19 lockdown). Materials and methods: From August 1st, 2019, until August 31st 2020, the hospital analytics determine the number of colonoscopies, screening colonoscopies, and surgeries. Results: During the given period number of detected and operated colorectal cancers was stable, except for April, when we mostly did not perform colonoscopies. Conclusion: We maintained a pre-COVID-19 pace in colorectal cancer treatment, colonoscopies, and colorectal surgery after epidemiological guidelines for colonoscopies and colorectal surgery were applied, owing to the relatively stable overall epidemiological situation.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42899008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-21DOI: 10.20471/LO.2020.48.02-03.12
T. Hudolin, V. Ferenčak, L. Penezić, T. Zekulić, T. Kuliš, M. Marić, O. Pavlović, A. El-Saleh, N. Knezevic, E. Goluža, B. Biočina, Z. Kastelan
Patients with non-metastatic, stage T3 clear-cell renal cell cancer present a clinical challenge for urologists. The extent of tumor thrombus in inferior vena cava is the primary determinant of surgical procedure complexity. Level III and IV thrombi require the use of cardiopulmonary bypass and hypothermic arrest. Careful preoperative planning and a multidisciplinary approach are mandatory. In this paper, we report outcomes of 12 patients who were surgically treated in our center. The 29 months overall survival for all patients was 69%, while three patients died during follow-up. Of nine surviving patients, six are currently disease-free, whereas three had disease progression. Our study showed that carefully selected patients with clear-cell renal cell carcinoma with inferior vena cava tumor thrombus level III and IV could be successfully treated with an aggressive surgical approach.
{"title":"Multidisciplinary surgical treatment of clear-cell renal carcinoma with inferior vena cava tumor thrombus level III and IV: our experience during the past decade","authors":"T. Hudolin, V. Ferenčak, L. Penezić, T. Zekulić, T. Kuliš, M. Marić, O. Pavlović, A. El-Saleh, N. Knezevic, E. Goluža, B. Biočina, Z. Kastelan","doi":"10.20471/LO.2020.48.02-03.12","DOIUrl":"https://doi.org/10.20471/LO.2020.48.02-03.12","url":null,"abstract":"Patients with non-metastatic, stage T3 clear-cell renal cell cancer present a clinical challenge for urologists. The extent of tumor thrombus in inferior vena cava is the primary determinant of surgical procedure complexity. Level III and IV thrombi require the use of cardiopulmonary bypass and hypothermic arrest. Careful preoperative planning and a multidisciplinary approach are mandatory. In this paper, we report outcomes of 12 patients who were surgically treated in our center. The 29 months overall survival for all patients was 69%, while three patients died during follow-up. Of nine surviving patients, six are currently disease-free, whereas three had disease progression. Our study showed that carefully selected patients with clear-cell renal cell carcinoma with inferior vena cava tumor thrombus level III and IV could be successfully treated with an aggressive surgical approach.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42168203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-21DOI: 10.20471/LO.2020.48.02-03.11
Ana Car-Peterko, M. Avirović, Iva Skočilić, P. Valković-Zujić, ingrid Belac-Lovasić, F. Lovasić
Background: Following breast cancer treatment recommendations, the conservative approach is accepted and highly respected in the Clinical Hospital Center (CHC) Rijeka. However, we have found that institutional follow-up data are lacking. This retrospective analysis aims to update institutional data on survival and disease control rates. Methods: From 2011 till 2014, 915 breast cancer patients underwent surgery at CHC Rijeka, and 615 were included in this analysis. The Institutional Ethics Committee approved the analysis. Results: All patients were female, and the average age was 59 years. In the 5-year postoperative period, local, regional, and distant recurrence-free survival rates and overall survival and disease-free survival were calculated. All rates negatively correlate with a higher T and N status and a higher stage of the disease. The analysis has also demonstrated that in the pT1-3 pN0-1 subgroup, sentinel lymph node biopsy (SLNB) was not inferior to axillary lymph node dissection (ALND) in terms of locoregional control of disease and overall survival. Conclusion: Besides updating institutional data, the analysis confirmed that overall survival and locoregional control of the disease in the upfront-surgery patients are similar between pN0 and pN1 subpopulations and between pN2 and pN3, but statistically significantly different between pN0-1 and pN2-3. Currently ongoing, prospective observational multicenter clinical trial aims to translate the significance of these results into the neoadjuvant era.
{"title":"Overall survival and disease control rates for operable invasive breast cancer in the era of conservative surgery; retrospective, institutional, and five-year follow-up data","authors":"Ana Car-Peterko, M. Avirović, Iva Skočilić, P. Valković-Zujić, ingrid Belac-Lovasić, F. Lovasić","doi":"10.20471/LO.2020.48.02-03.11","DOIUrl":"https://doi.org/10.20471/LO.2020.48.02-03.11","url":null,"abstract":"Background: Following breast cancer treatment recommendations, the conservative approach is accepted and highly respected in the Clinical Hospital Center (CHC) Rijeka. However, we have found that institutional follow-up data are lacking. This retrospective analysis aims to update institutional data on survival and disease control rates. Methods: From 2011 till 2014, 915 breast cancer patients underwent surgery at CHC Rijeka, and 615 were included in this analysis. The Institutional Ethics Committee approved the analysis. Results: All patients were female, and the average age was 59 years. In the 5-year postoperative period, local, regional, and distant recurrence-free survival rates and overall survival and disease-free survival were calculated. All rates negatively correlate with a higher T and N status and a higher stage of the disease. The analysis has also demonstrated that in the pT1-3 pN0-1 subgroup, sentinel lymph node biopsy (SLNB) was not inferior to axillary lymph node dissection (ALND) in terms of locoregional control of disease and overall survival. Conclusion: Besides updating institutional data, the analysis confirmed that overall survival and locoregional control of the disease in the upfront-surgery patients are similar between pN0 and pN1 subpopulations and between pN2 and pN3, but statistically significantly different between pN0-1 and pN2-3. Currently ongoing, prospective observational multicenter clinical trial aims to translate the significance of these results into the neoadjuvant era.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67598494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-21DOI: 10.20471/LO.2020.48.02-03.09
N. Obajdin, Đeni Smoilović-Radojčić, Dag Zahirović, Manda Švabić-Kolacio, David Rajlić, ingrid Belac-Lovasić, S. Jurković
Introduction: Within the past two decades, we made significant progress in radiation therapy for prostate cancer. At UH Rijeka IMRT became the technique of choice for radiation therapy following radical prostatectomy since 2016. Previously, an advanced 3-DCRT technique using the field-in-field (FiF) method was used for dose distribution optimization around target volumes and organs-at-risk. This research has been performed to investigate the influence of planning technique choice (FiF or IMRT) on coverage of target volumes with prescribed dose and organs-at-risk sparing. Materials and methods: Comparison of dose distributions calculated using FiF and IMRT techniques was performed retrospectively for ten patients who underwent postoperative radiotherapy. The prescribed dose for all patients was delivered using IMRT, and for this research, we also calculated dose distributions using the FiF technique. For FiF and IMRT techniques, we used linear accelerator photon beams. To determine the influence of planning technique on dose distribution parameters related to target volumes (GTV, CTV, PTV1, PTV2) were analyzed. For organs-at-risk sparing evaluation (rectum, bladder, femoral heads), we used dose-volume constraints. Results and discussion: The analysis of parameters related to target volumes has shown that most of them had no statistically significant difference (V100%(GTV), V100%(CTV), V95%(PTV2), V95%(PTV1)). For both planning techniques, internationally set dose constraints were achieved. Statistically, we found a significant difference for V100%(PTV2), p=0,000534, and V100%(PTV1), p=0,042944 in favor of IMRT. A statistically significant difference (p=0,045966) was found for the volume of the rectum, which receives 40Gy, and for the volume of femoral heads, which receives 30Gy (p=0,000385), where the sparing is better for IMRT. For dose-volume constraints related to the bladder, no statistically significant differences were found. Conclusion: Results of this research show a statistically significant difference for V100% target volume coverage for PTV1 and PTV2, with better dose coverage accomplished by IMRT. Concerning organs-at-risk sparing, a statistically significant difference in favor of IMRT was found for rectum volume, which receives 40Gy. Expectedly, IMRT was superior to the FiF technique. However, differences between the two planning techniques were relatively small, which points to the fact that the FiF technique is viable as a technique of choice.
{"title":"Comparison of two planning techniques (FiF/IMRT) for postoperative radiation therapy of prostate cancer","authors":"N. Obajdin, Đeni Smoilović-Radojčić, Dag Zahirović, Manda Švabić-Kolacio, David Rajlić, ingrid Belac-Lovasić, S. Jurković","doi":"10.20471/LO.2020.48.02-03.09","DOIUrl":"https://doi.org/10.20471/LO.2020.48.02-03.09","url":null,"abstract":"Introduction: Within the past two decades, we made significant progress in radiation therapy for prostate cancer. At UH Rijeka IMRT became the technique of choice for radiation therapy following radical prostatectomy since 2016. Previously, an advanced 3-DCRT technique using the field-in-field (FiF) method was used for dose distribution optimization around target volumes and organs-at-risk. This research has been performed to investigate the influence of planning technique choice (FiF or IMRT) on coverage of target volumes with prescribed dose and organs-at-risk sparing. Materials and methods: Comparison of dose distributions calculated using FiF and IMRT techniques was performed retrospectively for ten patients who underwent postoperative radiotherapy. The prescribed dose for all patients was delivered using IMRT, and for this research, we also calculated dose distributions using the FiF technique. For FiF and IMRT techniques, we used linear accelerator photon beams. To determine the influence of planning technique on dose distribution parameters related to target volumes (GTV, CTV, PTV1, PTV2) were analyzed. For organs-at-risk sparing evaluation (rectum, bladder, femoral heads), we used dose-volume constraints. Results and discussion: The analysis of parameters related to target volumes has shown that most of them had no statistically significant difference (V100%(GTV), V100%(CTV), V95%(PTV2), V95%(PTV1)). For both planning techniques, internationally set dose constraints were achieved. Statistically, we found a significant difference for V100%(PTV2), p=0,000534, and V100%(PTV1), p=0,042944 in favor of IMRT. A statistically significant difference (p=0,045966) was found for the volume of the rectum, which receives 40Gy, and for the volume of femoral heads, which receives 30Gy (p=0,000385), where the sparing is better for IMRT. For dose-volume constraints related to the bladder, no statistically significant differences were found. Conclusion: Results of this research show a statistically significant difference for V100% target volume coverage for PTV1 and PTV2, with better dose coverage accomplished by IMRT. Concerning organs-at-risk sparing, a statistically significant difference in favor of IMRT was found for rectum volume, which receives 40Gy. Expectedly, IMRT was superior to the FiF technique. However, differences between the two planning techniques were relatively small, which points to the fact that the FiF technique is viable as a technique of choice.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43281455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-21DOI: 10.20471/LO.2020.48.02-03.15
Iva Andrašek, M. Ravlić, Martina Mikulandra, F. Cmrečak, Sara Bilić-Knežević, L. Beketić-Orešković
Cancer of an unknown primary site is most commonly an aggressive metastatic tumor with a median patient survival of 6 to 9 months. Histologically, it is predominantly adenocarcinoma, and if the primary site is subsequently diagnosed, it is usually the pancreas or lung. Biopsy should be performed whenever possible to classify a tumor of unknown primary origin into one of the following entities: adenocarcinoma, poorly differentiated carcinoma with characteristics similar to adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, poorly differentiated neoplasm. After determining the primary tumor type, the subtype is determined by immunohistochemical staining. In oligometastatic disease, there is a possibility of surgical treatment. Radiotherapy is used as a part of combined modality treatment. Most patients with cancer of unknown primary have an unfavorable prognosis despite multiple chemotherapy agents, and no protocol can be recommended as standard therapy.
{"title":"Management of cancer of unknown primary","authors":"Iva Andrašek, M. Ravlić, Martina Mikulandra, F. Cmrečak, Sara Bilić-Knežević, L. Beketić-Orešković","doi":"10.20471/LO.2020.48.02-03.15","DOIUrl":"https://doi.org/10.20471/LO.2020.48.02-03.15","url":null,"abstract":"Cancer of an unknown primary site is most commonly an aggressive metastatic tumor with a median patient survival of 6 to 9 months. Histologically, it is predominantly adenocarcinoma, and if the primary site is subsequently diagnosed, it is usually the pancreas or lung. Biopsy should be performed whenever possible to classify a tumor of unknown primary origin into one of the following entities: adenocarcinoma, poorly differentiated carcinoma with characteristics similar to adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, poorly differentiated neoplasm. After determining the primary tumor type, the subtype is determined by immunohistochemical staining. In oligometastatic disease, there is a possibility of surgical treatment. Radiotherapy is used as a part of combined modality treatment. Most patients with cancer of unknown primary have an unfavorable prognosis despite multiple chemotherapy agents, and no protocol can be recommended as standard therapy.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48452713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-07-07DOI: 10.20471/lo.2020.48.01.03
S. Ramić, M. Perić-Balja, V. Ramljak, Sara Zadro, I. Kirac, T. Orešić, I. Milas
formed difference in logic MATERIALS METHODS: Data was collected retrospectively in a single high volume center for women diag nosed with invasive BC in the period before the introduction of mammography screening (2005-2007; N=1833), and from newly diagnosed (2017-2019; N=2676). Statistical significance of the findings was evaluated using Chi square test. RESULTS: We recorded a 31.5% increase in the number of patients referred to our hospital in the post-screening period. However, no statistically significant reduction in tumor size, histological grade or the number of positive axillary lymph nodes was detected in newly diagnosed BC compared to those diagnosed over ten years ago. The mean age of BC incidence was 61 years, with the mean tumor size of 22 mm (median 18 mm), in both periods. The significant difference occurred in the distribu tion of the intrinsic subtypes of BC (P<.001). About 45% of patients were diagnosed with pT1N0 stage, in both periods. CONCLUSION: In the post-screening period, we treated 32% more newly diagnosed breast cancers. However, patho histological features of BC, along with the average tumor size, did not change.
{"title":"Histopathological features of breast cancer from 2005 to 2019 in a single center in Croatia: an overview of changes following the introduction of mammography screening","authors":"S. Ramić, M. Perić-Balja, V. Ramljak, Sara Zadro, I. Kirac, T. Orešić, I. Milas","doi":"10.20471/lo.2020.48.01.03","DOIUrl":"https://doi.org/10.20471/lo.2020.48.01.03","url":null,"abstract":"formed difference in logic MATERIALS METHODS: Data was collected retrospectively in a single high volume center for women diag nosed with invasive BC in the period before the introduction of mammography screening (2005-2007; N=1833), and from newly diagnosed (2017-2019; N=2676). Statistical significance of the findings was evaluated using Chi square test. RESULTS: We recorded a 31.5% increase in the number of patients referred to our hospital in the post-screening period. However, no statistically significant reduction in tumor size, histological grade or the number of positive axillary lymph nodes was detected in newly diagnosed BC compared to those diagnosed over ten years ago. The mean age of BC incidence was 61 years, with the mean tumor size of 22 mm (median 18 mm), in both periods. The significant difference occurred in the distribu tion of the intrinsic subtypes of BC (P<.001). About 45% of patients were diagnosed with pT1N0 stage, in both periods. CONCLUSION: In the post-screening period, we treated 32% more newly diagnosed breast cancers. However, patho histological features of BC, along with the average tumor size, did not change.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2020.48.01.03","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41826287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-07-07DOI: 10.20471/lo.2020.48.01.06
T. Kuliš, T. Zekulić, M. Ćorić, M. Marić, N. Knezevic, Ivana Pušenjak, T. Hudolin, Z. Kastelan
1Department of Urology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia; 2Department of Pathology and Cytology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia; 3Department of Anesthesiology, Reanimatology and Intensive Care, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia
{"title":"Large fibroepithelial polyp in prostatic urethra of 29-year-old male patient","authors":"T. Kuliš, T. Zekulić, M. Ćorić, M. Marić, N. Knezevic, Ivana Pušenjak, T. Hudolin, Z. Kastelan","doi":"10.20471/lo.2020.48.01.06","DOIUrl":"https://doi.org/10.20471/lo.2020.48.01.06","url":null,"abstract":"1Department of Urology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia; 2Department of Pathology and Cytology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia; 3Department of Anesthesiology, Reanimatology and Intensive Care, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43694347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：